Provider: Nature Publishing Group
Content: application/x-research-info-systems
TY  - JOUR
AU  - Shiver, J. W.
TI  - Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
JA  - Nature
PY  - 2002///
VL  - 415
SP  - 331
EP  - 335
M3  - 10.1038/415331a
N1  - 10.1038/415331a
UR  - http://dx.doi.org/10.1038/415331a
ER  -

TY  - JOUR
AU  - Sullivan, N. J.
TI  - Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
JA  - Nature
PY  - 2003///
VL  - 424
SP  - 681
EP  - 684
M3  - 10.1038/nature01876
N1  - 10.1038/nature01876
UR  - http://dx.doi.org/10.1038/nature01876
ER  -

TY  - JOUR
AU  - Shiver, J. W.
AU  - Emini, E. A.
TI  - Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors
JA  - Annu. Rev. Med.
PY  - 2004///
VL  - 55
SP  - 355
EP  - 372
M3  - 10.1146/annurev.med.55.091902.104344
N1  - 10.1146/annurev.med.55.091902.104344
UR  - http://dx.doi.org/10.1146/annurev.med.55.091902.104344
ER  -

TY  - JOUR
AU  - Vogels, R.
TI  - Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell interaction and bypass of preexisting adenovirus immunity
JA  - J. Virol.
PY  - 2003///
VL  - 77
SP  - 8263
EP  - 8271
M3  - 10.1128/JVI.77.15.8263-8271.2003
N1  - 10.1128/JVI.77.15.8263-8271.2003
UR  - http://dx.doi.org/10.1128/JVI.77.15.8263-8271.2003
ER  -

TY  - JOUR
AU  - Kostense, S.
TI  - Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector
JA  - AIDS
PY  - 2004///
VL  - 18
SP  - 1213
EP  - 1216
M3  - 10.1097/00002030-200405210-00019
N1  - 10.1097/00002030-200405210-00019
UR  - http://dx.doi.org/10.1097/00002030-200405210-00019
ER  -

TY  - JOUR
AU  - Sumida, S. M.
TI  - Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein
JA  - J. Immunol.
PY  - 2005///
VL  - 174
SP  - 7179
EP  - 7185
ER  -

TY  - JOUR
AU  - Barouch, D. H.
TI  - Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity
JA  - J. Immunol.
PY  - 2004///
VL  - 172
SP  - 6290
EP  - 6297
ER  -

TY  - JOUR
AU  - Casimiro, D. R.
TI  - Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
JA  - J. Virol.
PY  - 2003///
VL  - 77
SP  - 6305
EP  - 6313
M3  - 10.1128/JVI.77.11.6305-6313.2003
N1  - 10.1128/JVI.77.11.6305-6313.2003
UR  - http://dx.doi.org/10.1128/JVI.77.11.6305-6313.2003
ER  -

TY  - JOUR
AU  - Youil, R.
TI  - Hexon gene switch strategy for the generation of chimeric recombinant adenovirus
JA  - Hum. Gene Ther.
PY  - 2002///
VL  - 13
SP  - 311
EP  - 320
M3  - 10.1089/10430340252769824
N1  - 10.1089/10430340252769824
UR  - http://dx.doi.org/10.1089/10430340252769824
ER  -

TY  - JOUR
AU  - Gall, J. G.
AU  - Crystal, R. G.
AU  - Falck-Pedersen, E.
TI  - Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype
JA  - J. Virol.
PY  - 1998///
VL  - 72
SP  - 10260
EP  - 10264
ER  -

TY  - JOUR
AU  - Crawford-Miksza, L.
AU  - Schnurr, D. P.
TI  - Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues
JA  - J. Virol.
PY  - 1996///
VL  - 70
SP  - 1836
EP  - 1844
ER  -

TY  - JOUR
AU  - Athappilly, F. K.
AU  - Murali, R.
AU  - Rux, J. J.
AU  - Cai, Z.
AU  - Burnett, R. M.
TI  - The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9[thinsp]Å resolution
JA  - J. Mol. Biol.
PY  - 1994///
VL  - 242
SP  - 430
EP  - 455
M3  - 10.1006/jmbi.1994.1593
N1  - 10.1006/jmbi.1994.1593
UR  - http://dx.doi.org/10.1006/jmbi.1994.1593
ER  -

TY  - JOUR
AU  - Rux, J. J.
AU  - Kuser, P. R.
AU  - Burnett, R. M.
TI  - Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods
JA  - J. Virol.
PY  - 2003///
VL  - 77
SP  - 9553
EP  - 9566
M3  - 10.1128/JVI.77.17.9553-9566.2003
N1  - 10.1128/JVI.77.17.9553-9566.2003
UR  - http://dx.doi.org/10.1128/JVI.77.17.9553-9566.2003
ER  -

TY  - JOUR
AU  - Jones, T. A.
AU  - Zou, J. Y.
AU  - Cowan, S. W.
AU  - Kjeldgaard, M.
TI  - Improved methods for building protein models in electron density maps and the location of errors in these models
JA  - Acta Crystallogr. A
PY  - 1991///
VL  - 47
SP  - 110
EP  - 119
M3  - 10.1107/S0108767390010224
N1  - 10.1107/S0108767390010224
UR  - http://dx.doi.org/10.1107/S0108767390010224
ER  -

TY  - JOUR
AU  - Kraulis, P. J.
TI  - MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures
JA  - J. Appl. Crystallogr.
PY  - 1991///
VL  - 24
SP  - 946
EP  - 950
M3  - 10.1107/S0021889891004399
N1  - 10.1107/S0021889891004399
UR  - http://dx.doi.org/10.1107/S0021889891004399
ER  -

TY  - JOUR
AU  - Sprangers, M. C.
TI  - Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors
JA  - J. Clin. Microbiol.
PY  - 2003///
VL  - 41
SP  - 5046
EP  - 5052
M3  - 10.1128/JCM.41.11.5046-5052.2003
N1  - 10.1128/JCM.41.11.5046-5052.2003
UR  - http://dx.doi.org/10.1128/JCM.41.11.5046-5052.2003
ER  -

TY  - JOUR
AU  - Pitcher, C. J.
TI  - Development and homeostasis of T cell memory in rhesus macaque
JA  - J. Immunol.
PY  - 2002///
VL  - 168
SP  - 29
EP  - 43
ER  -

TY  - JOUR
AU  - Gahery-Segard, H.
TI  - Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity
JA  - J. Virol.
PY  - 1998///
VL  - 72
SP  - 2388
EP  - 2397
ER  -

TY  - JOUR
AU  - Hong, S. S.
AU  - Habib, N. A.
AU  - Franqueville, L.
AU  - Jensen, S.
AU  - Boulanger, P. A.
TI  - Identification of adenovirus (Ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative Ad (Addl1520) for treatment of liver tumors
JA  - J. Virol.
PY  - 2003///
VL  - 77
SP  - 10366
EP  - 10375
M3  - 10.1128/JVI.77.19.10366-10375.2003
N1  - 10.1128/JVI.77.19.10366-10375.2003
UR  - http://dx.doi.org/10.1128/JVI.77.19.10366-10375.2003
ER  -

TY  - JOUR
AU  - Wohlfart, C.
TI  - Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms
JA  - J. Virol.
PY  - 1988///
VL  - 62
SP  - 2321
EP  - 2328
ER  -

TY  - JOUR
AU  - Havenga, M. J.
TI  - Improved adenovirus vectors for infection of cardiovascular tissues
JA  - J. Virol.
PY  - 2001///
VL  - 75
SP  - 3335
EP  - 3342
M3  - 10.1128/JVI.75.7.3335-3342.2001
N1  - 10.1128/JVI.75.7.3335-3342.2001
UR  - http://dx.doi.org/10.1128/JVI.75.7.3335-3342.2001
ER  -

TY  - JOUR
AU  - Nanda, A.
TI  - Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys
JA  - J. Virol.
PY  - 2005///
VL  - 79
SP  - 14161
EP  - 14168
M3  - 10.1128/JVI.79.22.14161-14168.2005
N1  - 10.1128/JVI.79.22.14161-14168.2005
UR  - http://dx.doi.org/10.1128/JVI.79.22.14161-14168.2005
ER  -